Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells

Kui Li, Tarl Prow, Stanley M. Lemon, Michael R. Beard – 30 December 2003 – Data suggesting that the hepatitis C virus (HCV) core protein influences normal cellular processes remain controversial. To determine the effects of core on cellular gene expression in hepatocytes, we developed a human hepatoma (Huh7)‐derived cell line with tightly regulated core expression under the control of a tetracycline‐regulated promoter. Cells expressing core did not have impaired proliferative abilities.

Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha

Gianfranco Alpini, Leonardo Baiocchi, Shannon Glaser, Yoshiyuki Ueno, Marco Marzioni, Heather Francis, Jo Lynne Phinizy, Mario Angelico, Gene LeSage – 30 December 2003 – Accumulating bile acids (BA) trigger cholangiocyte proliferation in chronic cholestasis.

Mallory body—A disease‐associated type of sequestosome

Cornelia Stumptner, Andrea Fuchsbichler, Hans Heid, Kurt Zatloukal, Helmut Denk – 30 December 2003 – Mallory bodies (MBs) consist of abnormal keratins, ubiquitin, heat shock proteins, and the protein p62. p62 is encoded by an immediate‐early response gene that rapidly responds to a variety of extracellular signals involved in cell proliferation, differentiation, and particularly oxidative stress.

M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan

Yoshihiko Oka, Robert A. Waterland, J. Keith Killian, Catherine M. Nolan, Hong‐Seok Jang, Keiji Tohara, Seigo Sakaguchi, Tsuneyoshi Yao, Akinori Iwashita, Yutaka Yata, Terumi Takahara, Shin‐ichiro Sato, Kazuyuki Suzuki, Tomoyuki Masuda, Randy L. Jirtle – 30 December 2003 – Mannose 6‐phosphate/insulin‐like growth factor II receptor (M6P/IGF2R) tumor suppressor– gene mutation is an early event in human hepatocellular carcinoma (HCC) formation in the United States, but its role in hepatocarcinogenesis in Japan is unclear.

Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma

Hitoshi Yoshiji, Shigeki Kuriyama, Junichi Yoshii, Yasuhide Ikenaka, Ryuichi Noguchi, Daniel J. Hicklin, James Huber, Toshiya Nakatani, Hirohisa Tsujinoue, Koji Yanase, Hiroo Imazu, Hiroshi Fukui – 30 December 2003 – The growth of any solid tumor depends on angiogenesis. Among the known angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), are potent and representative factors involved in tumor development. It has been reported that bFGF and VEGF showed a synergistic effect in both in vitro and in vivo angiogenesis.

NF‐κB inhibition sensitizes hepatocytes to TNF‐induced apoptosis through a sustained activation of JNK and c‐Jun

Hailing Liu, Chau R. Lo, Mark J. Czaja – 30 December 2003 – Hepatocyte resistance to tumor necrosis factor α (TNF)‐induced apoptosis is dependent on activation of the transcription factor nuclear factor κB (NF‐κB). To determine the mechanism by which NF‐κB protects against TNF toxicity, the effect of NF‐κB inactivation on the proapoptotic c‐Jun NH2‐terminal kinase (JNK) signaling pathway was examined in the rat hepatocyte cell line RALA255‐10G.

The resistance of P. acnes–primed interferon γ–deficient mice to low‐dose lipopolysaccharide‐induced acute liver injury

Yoshiaki Shimizu, Julie A. Margenthaler, Keith Landeros, Naoki Otomo, Gerard Doherty, M. Wayne Flye – 30 December 2003 – Endotoxin has been identified as a principal mediator of sepsis, often with resulting multiple organ failure. Although interferon γ (IFN‐γ) has a central role in controlling bacterial infection through the activation of macrophages and T lymphocytes, it can also enhance the harmful effects of the inflammatory response.

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirin

Maria Buti, Francisco Sanchez‐Avila, Yoav Lurie, Carlos Stalgis, Auristela Valdés, Maria Martell, Rafael Esteban – 30 December 2003 – Pegylated interferon (peginterferon) alfa‐2b plus ribavirin achieves a higher sustained response rate in patients with genotype 1 chronic hepatitis C virus (HCV) than standard combination therapy. This study evaluated HCV kinetics throughout therapy with 2 doses of peginterferon alfa‐2b and ribavirin in 55 patients.

Subscribe to